Phenacemide
Phenurone (phenacemide) is a small molecule pharmaceutical. Phenacemide was first approved as Phenurone on 1982-01-01. It is used to treat complex partial epilepsy in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| nervous system diseases | D009422 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phenacemide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PHENURONE | AbbVie | N-007707 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| complex partial epilepsy | EFO_1000877 | D017029 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
104 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 2 | 6 | 2 | 11 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 3 | 2 | 2 | 2 | 8 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | 2 | 1 | 3 | 7 |
| Pain | D010146 | EFO_0003843 | R52 | — | 1 | 3 | 3 | — | 7 |
| Neuralgia | D009437 | EFO_0009430 | — | 1 | 3 | 1 | — | 5 | |
| Headache | D006261 | HP_0002315 | R51 | — | 1 | 2 | 1 | 1 | 5 |
| Psychotic disorders | D011618 | F20.81 | — | — | 1 | 3 | — | 4 | |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | 1 | 1 | 2 |
| Postoperative pain | D010149 | G89.18 | — | — | 1 | 1 | — | 2 | |
| Chronic pain | D059350 | HP_0012532 | — | — | — | 2 | — | 2 |
Show 8 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral nervous system diseases | D010523 | G64 | — | 2 | 2 | — | 1 | 4 | |
| Neoplasms | D009369 | C80 | — | — | 3 | — | — | 3 | |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | 2 | — | 1 | 3 |
| Dementia | D003704 | F03 | — | — | 2 | — | — | 2 | |
| Depression | D003863 | F33.9 | 1 | — | 1 | — | — | 2 | |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | — | 1 | 1 | — | — | 2 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 1 | — | 1 | — | — | 2 |
| Laryngeal diseases | D007818 | J38.7 | — | 2 | 2 | — | — | 2 | |
| Sleep initiation and maintenance disorders | D007319 | F51.01 | — | — | 1 | — | 1 | 2 | |
| Dyspepsia | D004415 | EFO_0008533 | K30 | — | 1 | 1 | — | 1 | 2 |
Show 17 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | 1 | 2 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 2 | — | — | — | 2 |
| Cocaine-related disorders | D019970 | F14 | — | 1 | — | — | — | 1 | |
| Head and neck neoplasms | D006258 | — | 1 | — | — | — | 1 | ||
| Laron syndrome | D046150 | Orphanet_633 | E34.321 | — | 1 | — | — | — | 1 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 1 | — | — | — | 1 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | 1 | — | — | — | 1 |
| Pruritus | D011537 | HP_0000989 | L29 | — | 1 | — | — | — | 1 |
| Biliary dyskinesia | D001657 | EFO_0007169 | — | 1 | — | — | — | 1 | |
| Brain injuries | D001930 | S06.9 | — | 1 | — | — | — | 1 |
Show 10 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 4 | — | — | — | 2 | 6 | ||
| Drug interactions | D004347 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | — | 1 | 1 | ||
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | 1 | 1 | ||
| Gastroesophageal reflux | D005764 | EFO_0003948 | K21 | — | — | — | — | 1 | 1 |
| Tension-type headache | D018781 | HP_0012228 | G44.2 | — | — | — | — | 1 | 1 |
| Central nervous system sensitization | D059333 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PHENACEMIDE |
| INN | phenacemide |
| Description | Phenacemide is a member of acetamides. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NC(=O)NC(=O)Cc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 63-98-9 |
| RxCUI | 33253 |
| ChEMBL ID | CHEMBL918 |
| ChEBI ID | 8049 |
| PubChem CID | 4753 |
| DrugBank | DB01121 |
| UNII ID | PAI7J52V09 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 90 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,141 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more